Abstract
Almost half of retroperitoneal (RP) sarcomas are liposarcomas (LPS). The large majority
of RP LPS are either well-differentiated LPS (WDLPS) or dedifferentiated LPS (DDLPS),
these latter further classified according to grading in G2 and G3 DDLPS.
Surgery is the only potentially curative treatment to achieve local control and possibly
cure in primary localized disease. Over the last decade, a better delineation of the
different histology-specific patterns of failure and the development of nomograms
predictors of outcome has led to a better management of these rare tumors, with a
special focus on non-surgical treatments. Available evidences – although far from
exhaustive – show that radiation therapy might have a role, if any, as neoadjuvant
treatment in locally aggressive histologies (i.e. WDLPS and G2 DDLPS), while it does
not seem beneficial for histologies with a higher metastatic risk (i.e. G3 DDLPS and
leiomyosarcoma). Neoadjuvant chemotherapy, instead, can be considered to reduce the
risk of distant metastasis while waiting for the results of an ongoing RCT (STRASS-2)
evaluating its effect in these tumors.
However, given the rarity of these diseases and the subsequent lack of strong evidences
to guide treatment, outcome improvement in these patients remains a challenge. Patients'
referral to a sarcoma center where a dedicated specialized multidisciplinary team
tailor optimal treatment on a case-by-case basis is crucial to ensure these patients
the best outcome. Refining available nomograms – e.g including molecular variables
– and identifying predictors of response/toxicity to chemotherapy and immunotherapy
might be significantly helpful in tailoring treatments to the patient's characteristics.
Also, new systemic agents are eagerly awaited for improving the management further.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- NETSARC/REPPS/RESOS and French Sarcoma Group–Groupe d'Etude des Tumeurs Osseuses (GSF-GETO) Networks. Surgery in reference centers improves survival of sarcoma patients: a nationwide study.Ann Oncol. 2019 Jul 1; 30 (Erratum in: Ann Oncol. 2019 Jun 05;: PMID: 31081028; PMCID: PMC6637376): 1143-1153https://doi.org/10.1093/annonc/mdz124
- Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation.Ann Oncol. 2019 Dec 1; 30: 2008-2009https://doi.org/10.1093/annonc/mdz408.PMID:31584607
- A call to action: Why sarcoma surgery needs to be centralized.Cancer. 2018 Dec 1; 124 (Epub 2018 Oct 14. PMID: 30317538): 4452-4454https://doi.org/10.1002/cncr.31749
- Survival benefit of the surgical management of retroperitoneal sarcoma in a reference center: a nationwide study of the French sarcoma group from the NetSarc database.Ann Surg Oncol. 2019 Jul; 26 (Epub 2019 May 7. PMID: 31065964): 2286-2293https://doi.org/10.1245/s10434-019-07421-9
- Is surgery for retroperitoneal sarcoma at "low-volume" hospitals a bad idea?.Cancer. 2018 Dec 1; 124 (Epub 2018 Oct 14. PMID: 30317541): 4447-4451https://doi.org/10.1002/cncr.31750
- Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.Ann Oncol. 2014 Mar; 25 (PMID: 24567518; PMCID: PMC4433510): 735-742https://doi.org/10.1093/annonc/mdt577
- Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma.Cancer. 2018 Dec 1; 124 (Epub 2018 Oct 14. PMID: 30317543; PMCID: PMC6289614): 4495-4503https://doi.org/10.1002/cncr.31699
- Variations in retroperitoneal soft tissue sarcoma outcomes by hospital type: a National cancer database analysis.JCO Oncol Pract. 2020 Sep; 16 (Epub 2020 Apr 8. PMID: 32267809): e991-e1003https://doi.org/10.1200/JOP.19.00460
- Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets.J Clin Oncol. 2013 May 1; 31 (Epub 2013 Mar 25. PMID: 23530096): 1649-1655https://doi.org/10.1200/JCO.2012.44.3747
- Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.Lancet Oncol. 2016 May; 17 (Epub 2016 Apr 5. PMID: 27068860): 671-680https://doi.org/10.1016/S1470-2045(16)00010-3
- Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group.Ann Surg. 2016 May; 263 (PMID: 26727100): 1002-1009https://doi.org/10.1097/SLA.0000000000001447
- Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: a study and novel nomogram from TARPSWG.Clin Cancer Res. 2019 Apr 15; 25 (Epub 2019 Feb 5. PMID: 30723141): 2664-2671https://doi.org/10.1158/1078-0432.CCR-18-2700
- Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2020 Oct; 21 (Epub 2020 Sep 14. PMID: 32941794): 1366-1377https://doi.org/10.1016/S1470-2045(20)30446-0
- New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration.Curr Opin Oncol. 2019 Jul; 31 (PMID: 30893150): 310-316https://doi.org/10.1097/CCO.0000000000000535
- The trans-atlantic retroperitoneal sarcoma working group (TARPSWG): "red wine or white.Ann Surg Oncol. 2016 Dec; 23 (Epub 2016 Sep 9. PMID: 27613555): 4418-4420https://doi.org/10.1245/s10434-016-5538-z
- Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group.Ann Surg Oncol. 2015 Jan; 22 (Epub 2014 Oct 15. PMID: 25316486): 256-263https://doi.org/10.1245/s10434-014-3965-2
- Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the transatlantic Australasian RPS working group.Ann Surg Oncol. 2021 Nov; 28 (Epub 2021 Apr 14. PMID: 33852100): 7873-7888https://doi.org/10.1245/s10434-021-09654-z
- Management of recurrent retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the trans-atlantic RPS working group.Ann Surg Oncol. 2016 Oct; 23 (Epub 2016 Aug 1. Erratum in: Ann Surg Oncol. 2017 May 11;: PMID: 27480354; PMCID: PMC5557018): 3531-3540https://doi.org/10.1245/s10434-016-5336-7
- Management of metastatic retroperitoneal sarcoma: a consensus approach from the trans-atlantic retroperitoneal sarcoma working group (TARPSWG).Ann Oncol. 2018 Apr 1; 29 (PMID: 29432564; PMCID: PMC6354678): 857-871https://doi.org/10.1093/annonc/mdy052
- Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection.Ann Surg Oncol. 2015 May; 22 (Epub 2014 Oct 10. PMID: 25300609): 1447-1454https://doi.org/10.1245/s10434-014-4130-7
- NCCN clinical practice guidelines in Oncology: soft tissue sarcoma - version 2.2021.2021
- Electronic address: clinical [email protected] Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.Ann Oncol. 2021 Nov; 32 (Epub 2021 Jul 22. PMID: 34303806): 1348-1365https://doi.org/10.1016/j.annonc.2021.07.006
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2018 Oct 1; 29 (Erratum for: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67. PMID: 30285214): iv268-iv269https://doi.org/10.1093/annonc/mdy321
- Percutaneous core needle biopsy in retroperitoneal sarcomas does not influence local recurrence or overall survival.Ann Surg Oncol. 2015 Mar; 22 (Epub 2014 Sep 5. PMID: 25190132): 853-858https://doi.org/10.1245/s10434-014-4059-x
- Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis.Mod Pathol. 2009 Feb; 22 (Epub 2008 Sep 26. PMID: 18820664): 223-231https://doi.org/10.1038/modpathol.2008.164
- Improved biopsy accuracy in retroperitoneal dedifferentiated liposarcoma.Ann Surg Oncol. 2020 Oct; 27 (Epub 2020 May 4. PMID: 32367501): 4574-4581https://doi.org/10.1245/s10434-020-08519-1
- Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma.Br J Surg. 2019 Mar; 106 (Epub 2019 Jan 24. PMID: 30675910): 395-403https://doi.org/10.1002/bjs.11064
- The role of 18 F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective study.J Surg Oncol. 2021 Mar; 123 (Epub 2021 Jan 14. PMID: 33444466): 1081-1087https://doi.org/10.1002/jso.26379
- Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence.Eur Radiol. 2015 Aug; 25 (Epub 2015 Feb 19. PMID: 25693667): 2214-2221https://doi.org/10.1007/s00330-015-3654-y
- Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system.Int J Cancer. 1984 Jan 15; 33: 37-42https://doi.org/10.1002/ijc.2910330108.PMID:6693192
- Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma.Am J Surg Pathol. 2015 Mar; 39 (PMID: 25581729): 383-393https://doi.org/10.1097/PAS.0000000000000366
- Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma.Ann Surg. 2016 Mar; 263 (PMID: 25915910; PMCID: PMC4619189): 593-600https://doi.org/10.1097/SLA.0000000000001149
- Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma.Ann Surg. 2003 Sep; 238 (discussion 370-1) (PMID: 14501502; PMCID: PMC1422708): 358-370https://doi.org/10.1097/01.sla.0000086542.11899.38
- Has the outcome for patients who undergo resection of primary retroperitoneal sarcoma changed over time? A study of time trends during the past 15 years.Ann Surg Oncol. 2021 Mar; 28 (Epub 2020 Oct 18. PMID: 33073340): 1700-1709https://doi.org/10.1245/s10434-020-09065-6
- Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.Ann Surg Oncol. 2008 Jun; 15 (Epub 2008 Apr 9. PMID: 18398663): 1585-1593https://doi.org/10.1245/s10434-007-9805-x
- Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group.Cancer. 2017 Jun 1; 123 (Epub 2017 Feb 2. PMID: 28152173): 1971-1978https://doi.org/10.1002/cncr.30572
- Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: a study from TARPSWG.Cancer. 2020 Nov 15; 126 (Epub 2020 Aug 14. PMID: 32797703): 4917-4925https://doi.org/10.1002/cncr.33139
- Identifying the minimum volume threshold for retroperitoneal soft tissue sarcoma resection: merging National data with consensus expert opinion.J Am Coll Surg. 2020 Jan; 230 (Epub 2019 Oct 28. PMID: 31672672): 151-160.e2https://doi.org/10.1016/j.jamcollsurg.2019.09.013
- Inoperable primary retroperitoneal sarcomas: clinical characteristics and reasons against resection at a single referral institution.Ann Surg Oncol. 2021 Feb; 28 (Epub 2020 Jul 6. PMID: 32632883): 1151-1157https://doi.org/10.1245/s10434-020-08789-9
- Why were non-metastatic primary retroperitoneal sarcoma not resected?.Abstr Book, 2018
- Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG.Ann Surg Oncol. 2012 Sep; 19 (Epub 2012 Apr 3. PMID: 22476756): 2981-2991https://doi.org/10.1245/s10434-012-2342-2
- Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection?.Ann Surg Oncol. 2014 Jul; 21 (Epub 2014 Apr 7. PMID: 24705628): 2136-2143https://doi.org/10.1245/s10434-014-3643-4
- Intraperitoneal invasion of retroperitoneal sarcomas: a risk factor for dismal prognosis.Ann Surg Oncol. 2019 Oct; 26 (Epub 2019 Jul 16. PMID: 31313035): 3535-3541https://doi.org/10.1245/s10434-019-07615-1
- Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control.J Clin Oncol. 2009 Jan 1; 27 (Epub 2008 Dec 1. PMID: 19047280): 31-37https://doi.org/10.1200/JCO.2008.18.0802
- Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients.Cancer. 2003 May 15; 97: 2530-2543https://doi.org/10.1002/cncr.11365.PMID:12733153
- Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register.Eur J Cancer. 2000 Apr; 36 (PMID: 10762742): 710-716https://doi.org/10.1016/s0959-8049(99)00287-7
- Impact of margin status and local recurrence on soft-tissue sarcoma outcomes.J Bone Joint Surg Am. 2013 Oct 16; 95 (PMID: 24132366): e151https://doi.org/10.2106/JBJS.L.01149
- Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group.Cancer. 2001 Jul 15; 92 (PMID: 11466691): 359-368https://doi.org/10.1002/1097-0142(20010715)92:2<359::aid-cncr1331>3.0.co;2-y
- A system for the surgical staging of musculoskeletal sarcoma.Clin Orthop Relat Res. 1980 Nov-Dec; (PMID: 7449206): 106-120
- Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients.J Clin Oncol. 2009 Jan 1; 27 (Epub 2008 Dec 1. PMID: 19047283): 24-30https://doi.org/10.1200/JCO.2008.17.8871
- Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas.Ann Oncol. 2012 Apr; 23 (Epub 2011 Jul 16. PMID: 21765179): 1067-1073https://doi.org/10.1093/annonc/mdr323
- Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control.Ann Surg Oncol. 2010 Jun; 17: 1507-1514https://doi.org/10.1245/s10434-010-1057-5.PMID:20393803
- Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence.J Bone Joint Surg Br. 2001 Nov; 83: 1149-1155https://doi.org/10.1302/0301-620x.83b8.12028.PMID:11764430
- The effect of the setting of a positive surgical margin in soft tissue sarcoma.Cancer. 2014 Sep 15; 120 (Epub 2014 Jun 3. PMID: 24894656): 2866-2875https://doi.org/10.1002/cncr.28793
- Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the transatlantic RPS working group.Ann Surg. 2018 May; 267 (PMID: 28394870): 959-964https://doi.org/10.1097/SLA.0000000000002250
- Long-term morbidity after multivisceral resection for retroperitoneal sarcoma.Br J Surg. 2015 Aug; 102 (Epub 2015 Jun 3. PMID: 26041724): 1079-1087https://doi.org/10.1002/bjs.9829
- A prospective observational study of multivisceral resection for retroperitoneal sarcoma: clinical and patient-reported outcomes 1 Year after surgery.Ann Surg Oncol. 2021 Jul; 28 (Epub 2020 Nov 11. PMID: 33175262): 3904-3916https://doi.org/10.1245/s10434-020-09307-7
- Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients-A propensity score analysis.J Surg Oncol. 2019 Mar; 119 (Epub 2018 Dec 16. PMID: 30554403): 318-323https://doi.org/10.1002/jso.25337
- Results of resection for recurrent or residual retroperitoneal sarcoma after failed primary treatment.Ann Surg Oncol. 2017 Jan; 24 (Epub 2016 Aug 23. PMID: 27554502): 211-218https://doi.org/10.1245/s10434-016-5523-6
- Radiation therapy in retroperitoneal sarcoma management.J Surg Oncol. 2018 Jan; 117 (Epub 2017 Nov 22. PMID: 29165813): 93-98https://doi.org/10.1002/jso.24892
- Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma?.Ann Oncol. 2013 Mar; 24 (Epub 2012 Nov 2. PMID: 23123508): 832-837https://doi.org/10.1093/annonc/mds516
- Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma.Eur J Surg Oncol. 2018 May; 44 (Epub 2018 Feb 9. PMID: 29472043): 571-579https://doi.org/10.1016/j.ejso.2018.02.001
- Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma.Ann Surg Oncol. 2002 May; 9: 346-354https://doi.org/10.1007/BF02573869.PMID:11986186
- Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas.Ann Surg. 2015 Jul; 262 (PMID: 25185464; PMCID: PMC4345136): 163-170https://doi.org/10.1097/SLA.0000000000000840
- Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database.Lancet Oncol. 2016 Jul; 17 (Epub 2016 May 17. PMID: 27210906): 966-975https://doi.org/10.1016/S1470-2045(16)30050-X
- Radiotherapy for retroperitoneal liposarcoma: a report from the transatlantic retroperitoneal sarcoma working group.Cancer. 2019 Apr 15; 125 (Epub 2019 Jan 2. PMID: 30602058; PMCID: PMC6590287): 1290-1300https://doi.org/10.1002/cncr.31927
- A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.Cancer. 2008 Aug 1; 113 (PMID: 18521899): 573-581https://doi.org/10.1002/cncr.23592
- EORTC soft tissue and bone sarcoma group and the NCIC clinical trials group sarcoma disease site committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.Lancet Oncol. 2012 Oct; 13 (Epub 2012 Sep 4. PMID: 22954508): 1045-1054https://doi.org/10.1016/S1470-2045(12)70346-7
- Long-term follow-up and post-relapse outcome of patients with localized retroperitoneal sarcoma treated in the Italian sarcoma group-soft tissue sarcoma (ISG-STS) protocol 0303.Ann Surg Oncol. 2017 Dec; 24 (Epub 2017 Oct 17. PMID: 29043525): 3872-3879https://doi.org/10.1245/s10434-017-6105-y
- European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.Lancet Oncol. 2010 Jun; 11 (Epub 2010 Apr 29. PMID: 20434400; PMCID: PMC3517819): 561-570https://doi.org/10.1016/S1470-2045(10)70071-1
- Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas.J Clin Oncol. 2000 Oct 1; 18: 3378-3383https://doi.org/10.1200/JCO.2000.18.19.3378.PMID:11013278
- A contemporary large single-institution evaluation of resected retroperitoneal sarcoma.Ann Surg Oncol. 2014 Jul; 21 (Epub 2014 Mar 11. PMID: 24615180): 2150-2158https://doi.org/10.1245/s10434-014-3616-7
- Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group.Eur J Cancer. 2014 Mar; 50 (Epub 2013 Dec 5. PMID: 24316063): 784-792https://doi.org/10.1016/j.ejca.2013.11.021
- Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial.Trials. 2021 Feb 12; 22 (PMCID: PMC7881463): 134https://doi.org/10.1186/s13063-021-05069-z.PMID:33579340
- European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol. 2014 Apr; 15 (Epub 2014 Mar 5. PMID: 24618336): 415-423https://doi.org/10.1016/S1470-2045(14)70063-4
- Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.Lancet Oncol. 2017 Jun; 18 (Epub 2017 May 9. Erratum in: Lancet Oncol. 2017 Jun;18(6):e301. PMID: 28499583): 812-822https://doi.org/10.1016/S1470-2045(17)30334-0
- Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and polish (PSG) sarcoma groups.J Clin Oncol. 2020 Jul 1; 38 (Epub 2020 May 18. PMID: 32421444): 2178-2186https://doi.org/10.1200/JCO.19.03289
- European organization for research and treatment of cancer soft tissue and bone sarcoma group. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European organization for research and treatment of cancer soft tissue and bone sarcoma group.Cancer. 2020 Jun 1; 126 (Epub 2020 Mar 4. PMID: 32129883): 2637-2647https://doi.org/10.1002/cncr.32795
- Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma.Cancer. 2010 May 15; 116 (PMID: 20209615): 2429-2436https://doi.org/10.1002/cncr.25057
- Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent.Ann Oncol. 2010 Feb; 21 (Epub 2009 Jul 21. PMID: 19622598): 397-402https://doi.org/10.1093/annonc/mdp298
- Analysis of differentiation changes and outcomes at time of first recurrence of retroperitoneal liposarcoma by transatlantic Australasian retroperitoneal sarcoma working group (TARPSWG).Ann Surg Oncol. 2021 Nov; 28 (Epub 2021 Apr 27. PMID: 33907921): 7854-7863https://doi.org/10.1245/s10434-021-10024-y
- Postoperative morbidity after resection of recurrent retroperitoneal sarcoma: a report from the transatlantic Australasian RPS working group (TARPSWG).Ann Surg Oncol. 2021 May; 28 (Epub 2021 Jan 2. PMID: 33389288): 2705-2714https://doi.org/10.1245/s10434-020-09445-y
- Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule.Ann Surg. 2009 Dec; 250 (PMID: 19953716; PMCID: PMC3248745): 977-982https://doi.org/10.1097/sla.0b013e3181b2468b
- Groupe Sarcome Francais-Groupe D'etude Des Tumeurs Osseuses. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group.Clin Oncol. 2015 Jan; 27 (Epub 2014 Oct 7. PMID: 25300878): 48-55https://doi.org/10.1016/j.clon.2014.09.010
- Progression after chemotherapy is a novel predictor of poor outcomes after pulmonary metastasectomy in sarcoma patients.J Am Coll Surg. 2011 May; 212 (Epub 2011 Mar 23. PMID: 21435923): 821-826https://doi.org/10.1016/j.jamcollsurg.2011.01.007
Article info
Publication history
Published online: May 06, 2022
Accepted:
April 25,
2022
Received in revised form:
April 15,
2022
Received:
January 16,
2022
Identification
Copyright
© 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
